Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
DAMAE MEDICAL One line pitch: Skinsight® is a medical device providing dermatologists a way to visualise skin tissues without being invasive, & more accurate in cancer detection. Market Analysis: The incidence of both non-melanoma and melanoma skin cancers has been multiplied by more than three between 1980 and 2005. Currently, between 2 and 3 million non-melanoma skin cancers and 132,000 melanoma skin cancers occur globally each year.One in every three cancers diagnosed is a skin cancer and one in every five Americans and one in three Australians will develop skin cancer in their lifetime.Diagnosis of skin cancers mainly depends on a clinical examination of suspicious lesions followed by a biopsy and histopathological analysis using an optical microscope. This process is long, inneficient and in need of modernisation. Business Proposition: Our device provides a way to see under your skin at a cellular level.Our innovation is a technology that meets all of the dermatological criteria (performed by one device in a single setting). SkinSight® combines all advantages in terms of resolution, penetration depth, imaging orientation. SkinSight® provides physicians with significant clinical advantages by allowing accurate assessment for all types of skin cancers without limitations, and for all invasiveness stages evaluation, with high resolution. SkinSight® thus appears as a key tool for the dermatologist to correctly diagnose and optimize the therapeutic management of their patients. Competitive Advantage: Several optical imaging techniques have been developed by European and US-based companies, to allow for in situ cutaneous tumors characterization in a non-invasive way: confocal microscopy (CM), optical coherence tomography (OCT), high definition OCT (HD-OCT). However, those systems are still limited in terms of imagery performance (such as resolution or imaging depth) resulting in limited clinical performances. Our device shows a better resolution, a higher penetration rate and can identify more pathologies while providing vertical images, very similar ot current histologies. Investment Attractiveness: DM represents a real opportunity for investements for several reasons. First, the Incidence of skin cancer is sadly increasing evert year, resulting in a growing market of the imaging device in dermatology. Public authorities are also mobilised and are therefore facilitating the market access and increasing awarness around early stage detection. Secondly, beyond the dermatology market our technology can also reach huge markets such as research in cosmetology or pharmaceuticals. Finally, DAMAE Medical could be traded to an industrial company as it is the case for many med tech strat ups from 2018, to giants such as GE, Phillips etc. COMPANY PROFILE • Website: www.damaemedical.fr • Activity: MedTech • Contact: BARUT Anais [email protected] • Location: 96 bis Boulevard Raspail 75006 France • Founded in: 17/09/2014 • Employees: 12 • Management: Barut Anais CEO Siret David CTO Dubois Arnaud CSO • Financial information (€): - Company stage: validation - Capital raised to date: IP Situation: - Monthly burn rate: SkinSight® uses a patented technology (ownership: CNRS, Université Paris Sud, Institut D'Optique Graduate School) and has reached a mature level of development. The device has been acknowledged by prestigious KOLs in skin cancer management and is now entering its clinical trial phase while obtaining regulatory approvals. - Capital seeking and date: • Investors: • Referred by: CNRS, Université Paris Sud, Institut d'Optique Graduate School